Impact of SGLT2 inhibitors on survival in gastrointestinal cancer patients undergoing chemotherapy and/or radiotherapy: a real-world data retrospective cohort study
Repurposing SGLT2 inhibitors for cancer treatment could potentially improve outcomes for GI cancer patients without causing significant side effects. Further clinical trials are needed to confirm these findings and establish the optimal condition for its application in GI cancer treatment.
Authors
- Alexis Germán Murillo Carrasco (ORCID: https://orcid.org/0000-0002-7372-2608)
- Tatiane Katsue Furuya (ORCID: https://orcid.org/0000-0003-4643-8254)
- Wen‐Jan Tuan (ORCID: https://orcid.org/0000-0003-3939-8979)
- Roger Chammas (ORCID: https://orcid.org/0000-0003-0342-8726)
- Lucas E. Flausino (ORCID: https://orcid.org/0000-0002-2800-0374)
Institutions
- Universidade de São Paulo (BR)
- Instituto do Câncer do Estado de São Paulo (BR)
- Penn State Milton S. Hershey Medical Center (US)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1186/s12885-025-13966-8
- Citations
- 9
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 11.65
Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico